175 related articles for article (PubMed ID: 30187992)
21. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
[TBL] [Abstract][Full Text] [Related]
22. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
23. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
24. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
25. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)
Chong TC; Wong ILK; Cui J; Law MC; Zhu X; Hu X; Kan JWY; Yan CSW; Chan TH; Chow LMC
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362047
[TBL] [Abstract][Full Text] [Related]
28. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
29. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
[TBL] [Abstract][Full Text] [Related]
30. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
31. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
[TBL] [Abstract][Full Text] [Related]
32. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Ito F; Miura M; Fujioka Y; Abumiya M; Kobayashi T; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N
Int J Hematol; 2021 Jan; 113(1):100-105. PubMed ID: 33025461
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2).
Dakhlaoui I; Vahdati S; Maalej E; Chabchoub F; Wiese M; Marco-Contelles J; Ismaili L
Bioorg Chem; 2021 Nov; 116():105326. PubMed ID: 34536930
[TBL] [Abstract][Full Text] [Related]
34. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
Antoni F; Bause M; Scholler M; Bauer S; Stark SA; Jackson SM; Manolaridis I; Locher KP; König B; Buschauer A; Bernhardt G
Eur J Med Chem; 2020 Apr; 191():112133. PubMed ID: 32105979
[TBL] [Abstract][Full Text] [Related]
35. A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo.
Kokubo S; Ohnuma S; Murakami M; Kikuchi H; Funayama S; Suzuki H; Kajiwara T; Yamamura A; Karasawa H; Sugisawa N; Ohsawa K; Kano K; Aoki J; Doi T; Naitoh T; Ambudkar SV; Unno M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830383
[TBL] [Abstract][Full Text] [Related]
36. Enhanced reversal of ABCG2-mediated drug resistance by replacing a phenyl ring in baicalein with a meta-carborane.
Kuhnert L; Kuhnert R; Sárosi MB; Lakoma C; Scholz BK; Lönnecke P; Hey-Hawkins E; Honscha W
Mol Oncol; 2024 Feb; 18(2):280-290. PubMed ID: 37727134
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.
Fan X; Bai J; Zhao S; Hu M; Sun Y; Wang B; Ji M; Jin J; Wang X; Hu J; Li Y
Toxicol In Vitro; 2019 Dec; 61():104642. PubMed ID: 31493543
[TBL] [Abstract][Full Text] [Related]
38. Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position.
Winter E; Gozzi GJ; Chiaradia-Delatorre LD; Daflon-Yunes N; Terreux R; Gauthier C; Mascarello A; Leal PC; Cadena SM; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
Drug Des Devel Ther; 2014; 8():609-19. PubMed ID: 24920885
[TBL] [Abstract][Full Text] [Related]
39. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
